Cost-effectiveness
PET/MRI
Rectal cancer
Staging
Journal
European journal of nuclear medicine and molecular imaging
ISSN: 1619-7089
Titre abrégé: Eur J Nucl Med Mol Imaging
Pays: Germany
ID NLM: 101140988
Informations de publication
Date de publication:
09 2021
09 2021
Historique:
received:
30
10
2020
accepted:
03
01
2021
pubmed:
10
3
2021
medline:
18
9
2021
entrez:
9
3
2021
Statut:
ppublish
Résumé
Rectal cancer is one of the most frequent causes of cancer-related morbidity and mortality in the world. Correct identification of the TNM state in primary staging of rectal cancer has critical implications on patient management. Initial evaluations revealed a high sensitivity and specificity for whole-body PET/MRI in the detection of metastases allowing for metastasis-directed therapy regimens. Nevertheless, its cost-effectiveness compared with that of standard-of-care imaging (SCI) using pelvic MRI + chest and abdominopelvic CT is yet to be investigated. Therefore, the aim of this study was to analyze the cost-effectiveness of whole-body For estimation of quality-adjusted life years (QALYs) and lifetime costs of diagnostic modalities, a decision model including whole-body In the base-case scenario, the strategy whole-body Based on the results of the analysis, use of whole-body
Identifiants
pubmed: 33686457
doi: 10.1007/s00259-021-05193-7
pii: 10.1007/s00259-021-05193-7
pmc: PMC8426298
doi:
Substances chimiques
Contrast Media
0
Fluorodeoxyglucose F18
0Z5B2CJX4D
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
3268-3276Subventions
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Informations de copyright
© 2021. The Author(s).
Références
In Vivo. 2019 Nov-Dec;33(6):2065-2070
pubmed: 31662539
Cancer Epidemiol. 2015 Oct;39(5):734-44
pubmed: 26277328
Eur J Nucl Med Mol Imaging. 2021 Apr;48(4):1235-1245
pubmed: 33034673
Eur J Nucl Med Mol Imaging. 2021 Jan;48(1):186-195
pubmed: 32561971
Radiother Oncol. 2018 Dec;129(3):435-440
pubmed: 30274721
Radiology. 2020 Feb;294(2):310-319
pubmed: 31793850
Eur J Radiol. 2019 Apr;113:225-231
pubmed: 30927951
Int J Cancer. 2018 Dec 1;143(11):2758-2766
pubmed: 30095162
J Nucl Med. 2016 Dec;57(12):2016-2021
pubmed: 27516448
Radiology. 2013 Dec;269(3):857-69
pubmed: 24009348
BMC Med Imaging. 2020 Feb 24;20(1):22
pubmed: 32093632
BMC Cancer. 2018 Nov 22;18(1):1156
pubmed: 30466408
Acta Oncol. 2016 May;55(5):638-43
pubmed: 26457338
Cell Mol Gastroenterol Hepatol. 2017 Jan 20;3(2):163-173
pubmed: 28275683
J Med Life. 2015;8 Spec Issue:12-4
pubmed: 26361505
Cardiovasc Intervent Radiol. 2018 Oct;41(10):1530-1544
pubmed: 29845348
Eur J Nucl Med Mol Imaging. 2020 Jan;47(1):51-60
pubmed: 31410538
Curr Colorectal Cancer Rep. 2018;14(5):129-137
pubmed: 30294248
Glob Health Action. 2018;11(1):1447828
pubmed: 29564962
World J Gastroenterol. 2014 Dec 7;20(45):16964-75
pubmed: 25493009
JAMA. 2016 Sep 13;316(10):1093-103
pubmed: 27623463
Surg Oncol. 2019 Dec;31:26-32
pubmed: 31493647
Clin Nephrol. 2018 Apr;89(4):260-268
pubmed: 29154749
Eur Radiol. 2018 Nov;28(11):4735-4747
pubmed: 29736846
Eur J Health Econ. 2020 Apr;21(3):321-334
pubmed: 31707584
Expert Rev Anticancer Ther. 2017 Aug;17(8):745-758
pubmed: 28636427
Natl Vital Stat Rep. 2019 May;68(4):1-66
pubmed: 31112121
Curr Treat Options Oncol. 2018 May 11;19(6):29
pubmed: 29752549
BJS Open. 2018 Jul 27;2(6):433-451
pubmed: 30511044
J Clin Oncol. 2020 Sep 1;38(25):2830-2838
pubmed: 32484754